SEOUL, South Korea, July 31, 2024 /PRNewswire/ -- V-Space Co., Ltd., a company selected for the 'Next Unicorn Project' jointly pursued by Kangwon Land, the Small and Medium Business Corporation, the Korea Mine Reclamation Corporation, and the Foundation of Large & Small Businesses and Agricultural & Fisheries Cooperation, has unveiled significant progress in the burgeoning field of Urban Air Mobility (UAM)/Advanced Air Mobility (AAM).
On July 12, V-Space announced the rollout of its first UAM aircraft, a major milestone for the 'Next Unicorn Project.' This groundbreaking aircraft will be delivered to the Korea Aviation High School in Taebaek, Gangwon Province, where it will serve as the country's sole educational UAM vehicle, contributing to the development of future aviation talent in South Korea.
The development of this UAM aircraft was spearheaded by Yoo Soo-ho, a lead researcher who graduated from Korea Aviation High School (formerly Taebaek Mechanical Technical High School) and majored in mechatronics engineering at Inha University. Yoo's leadership in this project sets a precedent of mentorship and inspiration for future generations of aviation professionals.
V-Space plans to leverage the delivery of the first UAM aircraft to Korea Aviation High School as a starting point for broader initiatives aimed at integrating UAM into various industries such as commerce, logistics, industry, residential, and leisure sectors. This includes creating a 'World's First UAM Demonstration and Specialized City' centered around the Donggang region in collaboration with local municipalities like Yeongwol County and Taebaek City. They also aim to establish UAM commercial demonstration routes, such as the Donggang tour course.
Notably, V-Space has been selected as the lead organization for the Ministry of Land, Infrastructure, and Transport's 'Korean Urban Air Mobility (K-UAM) Safety Operation System Core Technology Development' project, which is part of the government's 12 national strategic technologies and 10 national strategic technology projects. This role involves collaborating with the Ministry of Land, Infrastructure, and Transport, the Korea Institute of Aviation Safety Technology, and others to establish regulatory standards for safe UAM flight operations, cementing V-Space's status as a pioneering startup in the future mobility sector.
V-Space is also focused on securing key technologies related to safety through ongoing research in collaboration with the Ministry of Science and ICT, the Korea Electronics Technology Institute, and Hanwha Systems. This research includes developing and demonstrating an onboard intelligent avionics software platform for recognizing and responding to abnormal situations in urban air mobility.
Jobeom Dong, Chairman of V-Space, stated, "We are making comprehensive efforts to promote and develop regional industries in collaboration with Gangwon Special Self-Governing Province. By aligning with government initiatives and being selected as the lead organization for various national research and development projects, V-Space is solidifying its position as South Korea's leading UAM specialist. Our goal is to compete on the global stage and become a leading company in the urban air mobility market."
Following this delivery, V-Space plans to further develop and mass-produce hydrogen/electric UAMs, establish flying and Maintenance, Repair, and Overhaul (MRO) facilities utilizing Gangwon's infrastructure, and commercialize these efforts on a global scale. Detailed collaboration with local governments is underway to utilize Yeongwol's UAM infrastructure and air taxi demonstration bases, as well as the unique resources of Taebaek Mountain and Donggang for initial unmanned and manned UAM commercial demonstrations.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
THE KOREA INDUSTRY DAILY: V-Space Unveils First Urban Air Mobility (UAM) Aircraft Prototype
By Greenyn Biotechnology Co., Ltd.
TAIPEI and TAICHUNG, Sept. 9, 2024 /PRNewswire/ -- Modern lifestyles characterized by irregular routines, high-fat and high-salt diets, and a preference for refined foods, coupled with busy schedules, high stress, overeating, and insufficient physical activity, have led to the emergence of the modern civilization ailment known as "metabolic syndrome."
Metabolic syndrome encompasses issues like abnormal blood lipids, blood sugar, and abdominal obesity (central obesity). Insulin resistance is the primary cause of metabolic syndrome. Prolonged poor blood sugar control can easily lead to diabetes and even other chronic diseases. According to statistics from Ministry of Health, Labour and Welfare, the number of diabetes patients in Japan has exceeded 10 million, with an increasing trend as the population ages. Driven by this substantial demand, bitter melon extract emerged, leading to their popularity in the market.
Potential Plant Insulin
Bitter melon (Momordica charantia Linn.), a member of the Cucurbitaceae family, is a traditional Chinese herbal medicine. Many studies have confirmed that bitter melon contains various blood sugar-lowering components, primarily including terpenes, phytosterols, and peptides. There are many related products on the market extracted from bitter melon (see Table 1). The mechanisms of action range from improving insulin sensitivity, inhibiting glucose-degrading enzymes, to directly binding with insulin receptors(3). With various blood sugar regulation mechanisms, bitter melon has gained significant attention in the field of blood sugar control. However, research shows that if specific component structures are not extracted or if the product is only following market trends and not adequately utilized, over time, ineffective feedback from consumers may lead to market saturation, causing high-quality products to be overlooked.
Research on Commercial Bitter Melon Health Ingredients
Research on Patented Amino Peptide Sequence mcIRBP-19
In an environment saturated with products claiming to contain bitter melon peptides, many of these lack scientific validation of their functionality or physiological mechanisms. The market is chaotic, with products of varying quality. Due to the complex mechanism of blood sugar regulation, there is rarely a structure that can substitute for insulin in regulating blood sugar. It has been traditionally believed that small molecular peptides or large proteins with high absorption rates cannot bind to insulin receptors, thus their effectiveness is limited. However, Greenyn Biotechnology is still committed to in conducting in-depth research on bitter melon, focusing on the essential nature of the plant. They have verified that the specific amino peptide sequence mcIRBP-19, consisting of 19 amino acids, is a rare natural substance that can directly bind to the diabetes-causing target - the insulin receptor. They have completed structural sequencing and quantitative analysis, providing scientific evidence that repeatedly confirms its unique physiological function. Additionally, they have conducted multiple in vivo functional studies, which are detailed as follows:
Regulating Blood Sugar and Assisting in the Treatment of Diabetes
Diabetes is an irreversible disease, and its alarming annual increase rate of 25,000 cases is not the only cause for concern. The complications it leads to, such as retinopathy, neuropathy, and cardiovascular diseases, are even more significant.
Through animal experiments analyzing fasting blood sugar and post-meal blood sugar regulation capabilities, it was found that the patented amino peptide sequence 19 (mcIRBP-19) can reduce fasting blood sugar by 50% and glycosylated hemoglobin by 38%. Additionally, it maintains a balanced insulin level in the body. Furthermore, it prevents a significant increase in post-meal blood sugar, rapidly regulating blood sugar within 2 hours. Its exceptional ability to stabilize blood sugar can significantly reduce the occurrence of complications caused by diabetes, such as retinopathy.
Human clinical studies have shown (4) that the patented amino peptide sequence 19 (mcIRBP-19) can assist in significantly reducing fasting blood sugar and glycosylated hemoglobin within 12 weeks for individuals who have shown insufficient improvement with conventional diabetes medication. It can also effectively improve the quality of life for patients (5). For sub-healthy individuals with diabetes, mcIRBP-19 can help regulate fasting blood sugar, stabilize glycated hemoglobin, and prevent the onset of diabetes. These clinical trials have verified the potential efficacy of this ingredient
Reducing Body Fat, Blood Lipids, and Anti-Inflammation
In addition to unstable blood sugar, metabolic syndrome also involves issues with abnormal blood lipids, central obesity, and chronic inflammation. Animal experiments (6) have shown that the patented amino peptide sequence 19 (mcIRBP-19) can regulate fatty acid metabolism and genes related to fatty liver. It effectively reduces body fat percentage by 25.5%, significantly decreasing white fat in the liver. This helps prevent the occurrence of fatty liver and avoids liver damage. Furthermore, chronic inflammation, much like an internal fire, can lead to various diseases, including cancer. The patented sequence 19 peptide can effectively reduce the expression of inflammatory factors in various organs, thus preventing the onset of chronic diseases.
Conclusion
The human body is like a machine. When metabolic syndrome occurs, it's like screws gradually loosening. Continued operation can easily lead to machine failure, resulting in conditions such as chronic diseases and cancer. At such times, we urgently need a helper who can tighten the screws.
The structure of mcIRBP-19, with the potential of a plant-derived insulin, is extracted using patented technology. The functional 19 amino acids are fully sequenced. Through a series of animal and clinical experiments, it has been confirmed to stabilize both pre-meal and post-meal blood sugar levels, reduce body fat and blood lipids, and achieve anti-inflammatory effects while providing adjunctive treatment for diabetes. This not only brings a ray of hope to diabetes patients, preventing the deterioration of their condition, but also takes into account their quality of life. It offers everyone a safe and effective natural preventive health option for daily life.
Reference
1. Wang HY, et al. Food Chem Toxicol. (2014) 69:347-356.
2. Dallas LC, et al. J Med Food. (2011) 14:1496-1504.
3. Lo HY, et al. J Agric Food Chem. (2013) 61:2461-2468.
4. Hsu PK, et al. Nutrients (2020) 12:1252.
5. Pan F, et al. Risk Manag Healthc Policy. (2020) 13:2219-2226.
6. Patent Invention No. I580690, Republic of China.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Plant Insulin - mcIRBP-19: Natural Key to Blood Sugar Regulation
